Langdon S - Search Results

1

Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.

Gray TA, MacLaine NJ, Michie CO, Bouchalova P, Murray E, Howie J, Hrstka R, Maslon MM, Nenutil R, Vojtesek B, Langdon S, Hayward L, Gourley C, Hupp TR. Gray TA, et al. Among authors: langdon s. J Immunol Methods. 2012 Apr 30;378(1-2):20-32. doi: 10.1016/j.jim.2012.01.013. Epub 2012 Feb 15. J Immunol Methods. 2012. PMID: 22361111

2

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. Macleod K, et al. Among authors: langdon sp. Cancer Res. 2005 Aug 1;65(15):6789-800. doi: 10.1158/0008-5472.CAN-04-2684. Cancer Res. 2005. PMID: 16061661

3

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. O'Donnell AJ, et al. Endocr Relat Cancer. 2005 Dec;12(4):851-66. doi: 10.1677/erc.1.01039. Endocr Relat Cancer. 2005. PMID: 16322326

4

Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.

McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, Smyth JF, Langdon SP. McPhillips F, et al. Carcinogenesis. 2006 Apr;27(4):729-39. doi: 10.1093/carcin/bgi289. Epub 2005 Dec 6. Carcinogenesis. 2006. PMID: 16332724

5

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA. Kuske B, et al. Endocr Relat Cancer. 2006 Dec;13(4):1121-33. doi: 10.1677/erc.1.01257. Endocr Relat Cancer. 2006. PMID: 17158758

6

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.

Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP. Smyth JF, et al. Clin Cancer Res. 2007 Jun 15;13(12):3617-22. doi: 10.1158/1078-0432.CCR-06-2878. Clin Cancer Res. 2007. PMID: 17575226 Free article. Clinical Trial.

7

Hormone therapy for epithelial ovarian cancer.

Langdon SP, Smyth JF. Langdon SP, et al. Curr Opin Oncol. 2008 Sep;20(5):548-53. doi: 10.1097/CCO.0b013e3283063912. Curr Opin Oncol. 2008. PMID: 19106659 Review.

8

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP. Nagumo Y, et al. Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737968

9

Pertuzumab for the treatment of ovarian cancer.

Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ. Langdon SP, et al. Expert Opin Biol Ther. 2010 Jul;10(7):1113-20. doi: 10.1517/14712598.2010.487062. Expert Opin Biol Ther. 2010. PMID: 20465533 Review.

10

The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers.

Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, Langdon S, Murray E, Larionov A, Petrakova K, Muller P, Dixon MJ, Hupp TR, Vojtesek B. Hrstka R, et al. Among authors: langdon s. Oncogene. 2010 Aug 26;29(34):4838-47. doi: 10.1038/onc.2010.228. Epub 2010 Jun 7. Oncogene. 2010. PMID: 20531310

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

269 results

Search Page